首页> Research and practice in thrombosis and haemostasis> Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.

Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.

导出 LinkOut

翻译打印收藏纠错

第一作者： Víctor,Jiménez-Yuste

第一单位： Hematology Department, Hospital Universitario La Paz, IdiPAZ, Autónoma University, Madrid, Spain.

作者： Víctor,Jiménez-Yuste ^[1] ; Johannes,Oldenburg ^[2] ; Eunice,Tzeng ^[3] ; Elise,Lim ^[3] ; Fabian,Sanabria ^[4] ; Johnny,Mahlangu ^[5]

作者单位： Hematology Department, Hospital Universitario La Paz, IdiPAZ, Autónoma University, Madrid, Spain. ^[1] Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany. ^[2] Genentech, Inc., South San Francisco, California, USA. ^[3] F. Hoffmann-La Roche Ltd, Basel, Switzerland. ^[4] Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa. ^[5]

关键词 comorbidities comorbidity emicizumab hemophilia A prophylaxis

DOI 10.1016/j.rpth.2024.102405

PMID 38783987

发布时间 2024-05-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Research and practice in thrombosis and haemostasis

2024年8卷3期

102405页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Research and practice in thrombosis and haemostasis

2024年8卷3期

102405页

检索历史清除

Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.

Research and practice in thrombosis and haemostasis

相似文献

同项目论文

Research and practice in thrombosis and haemostasis

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.

Research and practice in thrombosis and haemostasis

相似文献

同项目论文

Research and practice in thrombosis and haemostasis

相关期刊

检索历史清除